In an interview aired on Friday’s episode of FBN’s “Craman Countdown,” Amgen CEO Robert Bradway announced the company’s decision to invest $1 billion in a facility in Columbus, Ohio.
“Does the number of construction and permanent employment add this portion?” asked Liz Claman, host of Fox Business Network.
“Well, we’re adding about $1 billion in investments today. We hope that as a result of this expansion we’ll permanently hire hundreds more staff,” Bradway replied. “So, we have an investment of about 1.5 billion people in Columbus and about 750 people working in biomanufacturing.”
According to Bradway, the move is part of a trend to return manufacturing to the United States, partly due to Trump administration’s policies.
“From 2018 to 2024, we invested about $5 billion in US manufacturing, generating about $12 billion in economic activity,” a pharmaceutical executive explained.
Bradway also touted Trump’s 2017 tax cut as the launch point for Amgen’s infrastructure foundation in the US.
“Our manufacturing base was born in the United States,” he said. “And most of the manufacturing industry in our business began in the US. Tax reforms in 2017 allowed us to gradually invest in the US, which is why we continue to expand our manufacturing base here.”
Follow Jeff Poor on x @jeff_poor
